Sales 2024 * | 3.5Cr 2.56Cr 214.02Cr | Sales 2025 * | 3.87Cr 2.83Cr 236.65Cr | Capitalization | 12Cr 8.47Cr 708.77Cr |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 3.31 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 3 x |
P/E ratio 2024 * |
18.2
x | P/E ratio 2025 * |
15.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 60.64% |
Latest transcript on Biosyent Inc.
Managers | Title | Age | Since |
---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 64 | 01/96/01 |
Robert March
DFI | Director of Finance/CFO | - | 10/18/10 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 01/14/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Sara Elford
BRD | Director/Board Member | 53 | 08/18/08 |
René Goehrum
CEO | Chief Executive Officer | 64 | 01/96/01 |
Peter Lockhard
BRD | Director/Board Member | 60 | 01/02/01 |
1st Jan change | Capi. | |
---|---|---|
+55.35% | 82TCr | |
+32.40% | 60TCr | |
-0.10% | 38TCr | |
+15.47% | 32TCr | |
+13.10% | 31TCr | |
+16.25% | 25TCr | |
+14.52% | 23TCr | |
+16.54% | 18TCr | |
+4.31% | 17TCr |